Abstract:<p>Cisplatin plays a key role in treating small cell lung cancer (SCLC); however, the rapid development of cisplatin resistance limits its treatment effect. The detailed mechanisms of cisplatin-resistance, particularly in SCLC, remain unclear. We analyzed the differentially expressed genes (DEGs) between cisplatin-resistant small cell lung cancer cell line H446/CDDP and its parental cell line H446, using the transcriptome sequencing technique. Gene ontology (GO) analysis and the subsequent tests demonstrated that the functions of protein ubiquitination and autophagy are more active in the H446/CDDP cells. Autophagy plays a protective role in the H446/CDDP cells by using the autophagy inhibitors, 3-methyladenine and bafilomycin A1. Moreover, antimalarial drugs that inhibit autophagy by increasing the pH of lysosomes can also enhance cisplatin-induced cell death.</p>

What problem does this paper attempt to address?

This paper attempts to solve the problem of small - cell lung cancer (SCLC) developing resistance to cisplatin. Specifically, the research aims to explore the cisplatin - resistance mechanism through transcriptome sequencing technology and reverse this resistance by inhibiting autophagy. ### Background and Problems 1. **Characteristics of Small - Cell Lung Cancer (SCLC)** - SCLC is the most aggressive subtype of lung cancer, accounting for approximately 13% - 15% of all lung cancer cases. - Although the overall response rate to initial treatment can reach 60%, recurrence and chemotherapy resistance are almost inevitable. - The effectiveness of second - line treatment is usually poor, resulting in an overall 5 - year survival rate of less than 5%. 2. **Cisplatin Resistance** - Cisplatin is an important drug for treating SCLC, but the rapid development of its resistance limits the treatment effect. - The detailed mechanism of cisplatin resistance is not fully understood yet. The main known mechanisms include abnormal expression of transporters, drug detoxification, increased DNA repair, and enhanced anti - apoptotic ability. ### Research Methods 1. **Establishment of Cisplatin - Resistant Cell Lines** - By gradually increasing the cisplatin concentration to screen H446 cells, a cisplatin - resistant cell line H446/CDDP was established. - The cisplatin - resistant ability of H446/CDDP cells was verified by the MTT assay. 2. **Transcriptome Sequencing Analysis** - The gene expression profiles of H446 and H446/CDDP cells were compared. - Gene Ontology (GO) analysis showed that the protein ubiquitination function was more active in H446/CDDP cells. 3. **Autophagy Activity Detection** - Through Western Blot and transmission electron microscopy observations, it was found that the autophagy activity in H446/CDDP cells was higher after cisplatin treatment. - Using autophagy inhibitors 3 - methyladenine (3 - MA) and bafilomycin A1 (Baf - A1) to inhibit autophagy, it was found that the cytotoxicity of cisplatin could be enhanced. 4. **The Role of Antimalarial Drugs** - Chloroquine (CQ) and hydroxychloroquine (HCQ) can inhibit autophagy by increasing the pH value of lysosomes. - The experimental results showed that the combined use of cisplatin and CQ or HCQ could significantly increase the mortality rate of H446/CDDP cells. ### Conclusions 1. **Cisplatin Resistance Mechanism** - The protein ubiquitination and autophagy activities were higher in cisplatin - resistant H446/CDDP cells. - Autophagy plays a protective role in these cells and helps them resist the cytotoxicity of cisplatin. 2. **Potential Treatment Strategies** - Inhibiting autophagy may be an effective method for treating cisplatin - resistant SCLC. - Antimalarial drugs such as CQ and HCQ can enhance the efficacy of cisplatin, providing new ideas for clinical applications. Through these studies, the authors revealed the protective role of autophagy in cisplatin - resistant SCLC cells and proposed potential treatment strategies, laying the foundation for further research and clinical applications.

Exploring the mechanism of cisplatin resistance by transcriptome sequencing and reversing the chemoresistance by autophagy inhibition in small cell lung cancer

Identification of candidate genes and pathways in cisplatin-resistant NSCLC by integrated bioinformatics analysis

Transcriptome Sequencing Reveals Key Pathways And Genes Associated With Cisplatin Resistance In Lung Adenocarcinoma A549 Cells

Hypoxia-Induced Autophagy Enhances Cisplatin Resistance in Human Bladder Cancer Cells by Targeting Hypoxia-Inducible Factor-1α

The Essential Role of H19 Contributing to Cisplatin Resistance by Regulating Glutathione Metabolism in High-Grade Serous Ovarian Cancer

Inhibition of autophagy enhanced chemosensitivity in cisplatin resistant hypopharyngeal squamous carcinoma cells

Integration of metabolomics and transcriptomics to reveal metabolic characteristics and key targets associated with cisplatin resistance in non-small cell lung cancer.

Next-Generation Sequencing Analysis of mRNA Profile in Cisplatin-Resistant Gastric Cancer Cell Line SGC7901

Inhibition of Autophagy by Andrographolide Resensitizes Cisplatin-Resistant Non-Small Cell Lung Carcinoma Cells Via Activation of the Akt/mTOR Pathway.

Autophagy Facilitates Lung Adenocarcinoma Resistance to Cisplatin Treatment by Activation of AMPK/mTOR Signaling Pathway.

Peptide-Based Autophagic Gene and Cisplatin Co-delivery Systems Enable Improved Chemotherapy Resistance

The regulation of autophagy by the miR-199a-5p/p62 axis was a potential mechanism of small cell lung cancer cisplatin resistance

Er Stress and Autophagy Are Involved in the Apoptosis Induced by Cisplatin in Human Lung Cancer Cells

DLX6-AS1 activated by H3K4me1 enhanced secondary cisplatin resistance of lung squamous cell carcinoma through modulating miR-181a-5p/miR-382-5p/CELF1 axis

Inhibition of Autophagy Improves Resistance and Enhances Sensitivity of Gastric Cancer Cells to Cisplatin.

Exosome-Reversed Chemoresistance to Cisplatin in Non-Small Lung Cancer Through Transferring miR-613

The role of microRNA in cisplatin resistance or sensitivity

Induction of Autophagy Contributes to Cisplatin Resistance in Human Ovarian Cancer Cells

Cisplatin and Starvation Differently Sensitize Autophagy in Renal Carcinoma: A Potential Therapeutic Pathway to Target Variegated Drugs Resistant Cancerous Cells

Autophagy Inhibitor Chloroquine Increases Sensitivity To Cisplatin In Qbc939 Cholangiocarcinoma Cells By Mitochondrial Ros

Hsa_circ_0096157 silencing suppresses autophagy and reduces cisplatin resistance in non-small cell lung cancer by weakening the Nrf2/ARE signaling pathway